Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.94 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3775695 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6692875 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372244 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6692872 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL5163322 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372670 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL25212993 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL8440714 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL20917176 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372534 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569864-B2 | Liquid dispensing product having a spray dispenser | THE PROCTER & GAMBLE COMPANY (US) | 2026-03-10 | — | — | US | claimed |
| US-20250230382-A1 | STABLE AQUEOUS SURFACTANT COMPOSITIONS | PROCTER & GAMBLE (US) | 2025-07-17 | — | — | US | claimed |
| CN-120057880-A | Method for preparing iron-based polyanion compound by liquid phase method and application thereof | 合肥国轩高科动力能源有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120039848-A | Ferric sodium manganese pyrophosphate anode material and preparation method and application thereof | 合肥国轩高科动力能源有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-12291693-B2 | Stable aqueous surfactant compositions | THE PROCTER & GAMBLE COMPANY (US) | 2025-05-06 | — | — | US | claimed |
| EP-4543200-A1 | HERBICIDE COMPOSITION FOR CONTROLLING WEEDS | The Procter & Gamble Company (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119798073-A | Preparation method of sodium citrate pentahydrate | 连云港树人科创食品添加剂有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-115726010-B | Nickel-copper-tungsten alloy with gradient structure and preparation method thereof | 国网河南省电力公司电力科学研究院 | 2025-03-28 | — | — | CN | claimed |
| EP-4510234-A1 | PRUSSIAN BLUE POSITIVE ELECTRODE MATERIAL AND PREPARATION METHOD THEREFOR, POSITIVE ELECTRODE SHEET AND SODIUM-ION BATTERY | HUBEI WANRUN NEW ENERGY TECHNOLOGY CO., LTD. (CN) | 2025-02-19 | — | — | EP | claimed |
| CN-119487164-A | Stable aqueous surfaces active agent composition | 宝洁公司 | 2025-02-18 | — | — | CN | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| CN-1635871-A | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2005-07-06 | — | — | CN | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
| EP-0079836-B1 | COMPOSITIONS BASED ON WATER-SOLUBLE GUMS, THEIR PREPARATION AND THEIR USE | RHONE-POULENC CHIMIE (FR) | 1987-01-21 | — | — | EP | claimed |
| EP-0078155-B1 | CROSSLINKING HALOGEN-CONTAINING POLYMER | HERCULES INCORPORATED (US) | 1986-03-05 | — | — | EP | claimed |
| US-4519844-A | HETEROPOLYSACCHARIDE AND WATER DONOR | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-05-28 | — | — | US | claimed |
| US-4482681-A | HYDRATED SALT | HERCULES INCORPORATED (US) | 1984-11-13 | — | — | US | claimed |
| EP-0078155-A1 | Crosslinking halogen-containing polymer | HERCULES INCORPORATED (US) | 1983-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569864-B2 | Liquid dispensing product having a spray dispenser | TGFBR2, MASTL, TRPM8 | CA4 4240/4885CASP1 3216/4885FFAR3 704/4885 |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | CA4 2466/4885CASP1 2019/4885FFAR3 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.